In human non-small-cell lung carcinomas (NSCLC), FGF2, FGF9, and their respective receptors, were also reported to mediate autocrine signaling which drives tumor resistance to specific kinase targeted therapy [142]. This evidence concerns the gene FGF2 and neoplasm.